 The Menarini Group and Radius Health Inc NASDAQ: RDUS have provided details on the elacestrant data from the EMERALD Phase 3 trial presented at the San Antonio Breast Cancer Symposium. As previously announced, the study met its two primary endpoints: progression-free survival PFS in the overall population and PFS in patients with tumors harboring Estrogen Receptor 1 ESR 1 mutations. 